Policy & Regulation
Telix Pharmaceuticals doses first patient in TLX250-CDx named patient (early access) program in Netherlands
4 December 2023 -

Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Monday that it has dosed its first patient in a named patient (early access) program in the Netherlands for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

Through this named patient program in the Netherlands (Leveren op Artsenverklaring), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.

The program follows the completion of Telix's successful global Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, ClinicalTrials.gov Identifier: NCT03849118), which reported positive results in November 2022, meeting all co-primary and secondary endpoints.